中国生物制药 6 款 1 类新药首次获批临床

Insight数据库
26 Jun

Insight 数据库显示,2025 年以来,中国生物制药已经有6 款 1 类新药首次在国内获批临床。从药物类型来看,包括 1 款 ADC、1 款双抗 ADC、2 款单抗、1 款 PROTAC、1 款化药。从适应症来看,4 款药物用于治疗肿瘤、1 款用于治疗甲状腺眼病(TED)、1 款用于放射性肺损伤的预防。TQB6411:EGFR/c-Met 双抗6 月 13 日,TQB6411 临床试验申请获...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10